← All indications
Monoclonal Gammopathy of Undetermined Significance
Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.
Subtype terms (1)
More specific conditions that are subtypes of Monoclonal Gammopathy of Undetermined Significance in the MeSH hierarchy.
- Schnitzler Syndrome
6 drugs (4 approved, 2 experimental)
Drugs by status
Phase 2 trials (18)
Phase 1 trials (4)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (7)
Organization Involved with Phase 2 Indications (17)
- Celgene
- Genentech
- Genzyme
- Biogen
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Center for Research Resources (NCRR)
- Harvard University
- Dartmouth University
- Marshall University
- Ohio State University
- University of Rochester
- Wayne State University
- Mayo Clinic
- Columbia University
- Janssen Pharmaceutica NV
- Edwards Foundation, Inc.
Organization Involved with Phase 1 Indications (6)